Navigation Links
The Treatment Landscape for Hepatocellular Carcinoma Will Change Dramatically Over the Next Ten Years Due to the Launch of New Therapies in the United States and EU5

BURLINGTON, Mass., Jan. 29, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the treatment landscape for hepatocellular carcinoma in the United States and Europe will change dramatically through 2021 as three new, potentially high priced therapies–Novartis's Afinitor, ArQule's tivantinib and Celsion's ThermoDox–arrive on the market, thereby greatly increasing treatment options in patient populations in which there is no approved standard-of-care drug therapy.

According to Niche Markets and Rare Diseases: Hepatocellular Carcinoma, of the forecasted emerging therapies, Afinitor will be the first drug to gain regulatory approval and will launch in 2014 in all markets under study for treatment of advanced hepatocellular carcinoma in the second-line setting following disease progression on Bayer HealthCare/Onyx Pharmaceuticals' Nexavar, the current patient-share leader. By 2021, tivantinib will also launch in the second-line setting for treatment of patients who express high levels of c-MET. ThermoDox, a heat-sensitive liposome-encapsulated formulation of doxorubicin, will be the only therapy to launch over the next ten years in the localized/locally advanced setting for use in combination with radiofrequency embolization (RFA).

"According to opinion leaders, one of the greatest unmet needs in the hepatocellular carcinoma space is for a second-line therapy directed at patients who cannot tolerate treatment with or progress on Nexavar–the standard-of-care in the first-line setting through 2021," said Decision Resources Analyst Karen Pomeranz , Ph.D. "However, the launch of ThermoDox will herald a novel treatment approach in localized/locally advanced disease. Most interviewed physicians are excited by this prospect because it could potentially increase the benefit of treatment with RFA for patients with disease confined to the liver and could also lead to an increase in treatment rates with RFA—particularly in the locally advanced setting."

In addition, the findings reveal that the number of incident cases of hepatocellular carcinoma in the major markets will increase by approximately 30 percent over the forecast period, driven by an aging population and an overall increase in risk. Drug treatment rates will also rise as new therapies come to market.

About Hepatocellular CarcinomaHepatocellular Carcinoma is offered as part of Decision Resources' Niche Markets and Rare Diseases service. Each report assesses opportunity in a select drug market across the United States, France, Germany, Italy, Spain and the United Kingdom. The report provides detailed coverage of patient populations, current therapies, unmet needs and emerging therapies, and includes primary research with country-specific thought leaders.

About Decision Resources
Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources Decision Resources GroupAllison Thrower

Liz Marshall781-993-2604 

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
3. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
5. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
(Date:12/1/2015)... --  MabVax Therapeutics Holdings, Inc . (OTCQB: MBVX), a ... an Investigational New Drug Application (IND) with the U.S. ... fully human antibody product HuMab 5B1 as a therapeutic ... the Phase I clinical trial early in 2016. ... planned Phase I trial will evaluate the safety, tolerability ...
(Date:12/1/2015)... 2015  Booth #3506 – Claymount is featuring its full ... of the Radiological Society of North America ... Based in the Netherlands , Claymount is ... (NYSE: VAR ) and is one of the world,s ... state automatic exposure control systems for controlling dose during medical ...
(Date:12/1/2015)... , Dec. 1, 2015  Lexicon Pharmaceuticals, ... that top-line data from its TELECAST Phase ... in treating carcinoid syndrome in cancer patients ... clinical benefit observed in its pivotal TELESTAR ... a companion to TELESTAR primarily to provide ...
Breaking Medicine Technology:
(Date:12/1/2015)... Viejo, CA (PRWEB) , ... December 01, 2015 , ... ... length of footage, and with full control over customization, the possibilities are truly endless, ... frame rate, position randomization, overlay depth position, vertical flip, horizontal flip, depth of field ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... receiving the 2015 HSJ Acute Sector Innovation Award on November 18th. This prestigious ... care experience, and propose exciting enhancements to the medical landscape. , The UCLH ...
(Date:11/30/2015)... Cary, NC (PRWEB) , ... November 30, 2015 ... ... Dominique Dawes, Amanda Beard and Brooke Bennett are collaborating with brands across various ... , These four influential figures make up an elite group of Gold Medal ...
(Date:11/30/2015)... , ... December 01, 2015 , ... ... Christina Colon as a 2015-2016 inductee into its VIP Woman of the ... NAPW is the nation’s leading networking organization exclusively for professional women, boasting 850,000 ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... programs of the19th Bi-National Convention of the Federation of Philippine American Chambers of ... in Las Vegas, Nevada. , 1Heart Caregiver Services, as an active delegate ...
Breaking Medicine News(10 mins):